Aurora Dadone
Research Subjects
Research Interests
Aurora Dadone has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Angelo Palmese
GSK, Via Fiorentina 1, 53100 Siena, Italy
1 shared publication - Cosimo-Walter D’acunto
Analytical Development Biotech—Global Analytical Development—Global Development & Launch—Global Healthcare Operation, Istituto di Ricerche Biomediche “Antoine Marxer” RBM S.p.A., Colleretto Giacosa, Via Ribes, 1, 10010 Samone, Italy
1 shared publication - Flavio Peroglio
GHO Ivrea QC & Scientific Excellence—Global Analytical Development—Global Development & Launch—Global Healthcare Operation, Istituto di Ricerche Biomediche “Antoine Marxer” RBM S.p.A., Colleretto Giacosa, Via Ribes, 1, 10010 Samone, Italy
1 shared publication - Francesco Nevelli
Analytical Development Biotech—Global Analytical Development—Global Development & Launch—Global Healthcare Operation, Istituto di Ricerche Biomediche “Antoine Marxer” RBM S.p.A., Colleretto Giacosa, Via Ribes, 1, 10010 Samone, Italy
1 shared publication - Monica Lispi
Merck Healthcare KGaA, 64293 Darmstadt, Germany
1 shared publication - Ralf Gleixner
Ares Trading S.A., Rue de l’Ouriette 151, 1170 Aubonne, Switzerland
1 shared publication
Latest Publications
- Open Access
- 28 April 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (9) , 8040
Biological Assay to Determine Gonadotropin Potency: From In Vivo to In Vitro Sustainable Method
Various preparations of follicle-stimulating hormone (FSH) are commercially available; however, they differ in glycoforms composition and purity owing to their respective sources. Additional chemical/physical changes can also be introduced during manufacturing and can impact their biological activity (biopotency), which is routinely assessed using an in vivo bioassay (Steelman–Pohley). This study aimed to determine whether an in vitro bioassay could assess biopotency by distinguishing between r-hFSH chemical/physical variants with similar ability to the in vivo bioassay. The specific activity (units of biological activity per mg of product) of variants of r-hFSH generated through enrichment (acidic/basic), stress (oxidative/acidic pH) and enzymatic treatment (desialylation and desialylation/degalactosylation) was compared using the in vivo and in vitro bioassays. The in vitro bioassay reliably detected potential chemical/physical modifications in r-hFSH variants that may impact biopotency. Overall, the methods demonstrated a comparable ability to detect changes in specific activities due to chemical/physical differences in r-hFSH variants. These data indicate that the in vitro bioassay is suitable to replace the in vivo bioassay.
- 28 April 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (9) , 8040
Open AccessBiological Assay to Determine Gonadotropin Potency: From In Vivo to In Vitro Sustainable Method
Various preparations of follicle-stimulating hormone (FSH) are commercially available; however, they differ in glycoforms composition and purity owing to their respective sources. Additional chemical/physical changes can also be introduced during manufacturing and can impact their biological activity (biopotency), which is routinely assessed using an in vivo bioassay (Steelman–Pohley). This study aimed to determine whether an in vitro bioassay could assess biopotency by distinguishing between r-hFSH chemical/physical variants with similar ability to the in vivo bioassay. The specific activity (units of biological activity per mg of product) of variants of r-hFSH generated through enrichment (acidic/basic), stress (oxidative/acidic pH) and enzymatic treatment (desialylation and desialylation/degalactosylation) was compared using the in vivo and in vitro bioassays. The in vitro bioassay reliably detected potential chemical/physical modifications in r-hFSH variants that may impact biopotency. Overall, the methods demonstrated a comparable ability to detect changes in specific activities due to chemical/physical differences in r-hFSH variants. These data indicate that the in vitro bioassay is suitable to replace the in vivo bioassay.